Table 2 shows references that report outcome of gene therapy trials targeting cardiovascular diseases.
In addition, gene therapy offers the possibility of long-term expression of therapeutic proteins in specific cells.
All patients died at 1-29 months from gene therapy.
Adenoviruses have been particularly exploited for cancer gene therapy.
Artificial chromosomes with several therapeutic genes inserted could be important additives to conventional gene therapy if efficiently delivered to target cells.
In the future, individually designed gene therapy will probably represent a therapeutic option.
This fact raises the question of the feasibility of very expensive, complicated and work-intensive gene therapy approaches for these diseases.
This case prompted a thorough revision of the safety standards for gene therapy trials.
